BNT162, a mRNA-based coronavirus vaccine, is being co-developed by Pfizer and BioNTech. It is expected to enter clinical testing in April 2020. BioNTech is also collaborating with Fosun Pharma to develop BNT162 for China.
You must be logged in to reply to this topic.
For comments and inquiries about the COVID-19 Pharmacology Resource Center, please fill out the Contact Us form, and we will be in touch shortly.